RBC Capital has revised its price target for ResMed (RMD, Financial), increasing it to $255 from the previous $247, while maintaining a Sector Perform rating on the stock. This decision follows the release of the company's third-quarter results, which demonstrated steady growth in both revenue and earnings.
Despite the results meeting market expectations, a notable aspect of the report was the continued exemption of ResMed's products from U.S. import tariffs. This provides a positive outlook for the company, potentially improving its competitive position in the market. The update may offer reassurance to investors regarding the firm’s stability and prospects.
